17 results about "Intravenous use" patented technology

1. Name of the product in this design: Intravenous drip sensor (rechargeable). 2. Purpose of this design: For use as a vein drip sensor. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

To provide a therapeutic and / or prophylactic agent for mycosis, which is excellent in safety and effectiveness, is administered to a Japanese mycosis patient, and contains isavuconazole or a prodrug thereof as an active ingredient.SOLUTION: A therapeutic and / or prophylactic agent for mycosis, which is administered according to a loading dosing regimen, and further administered according to a maintenance dosing regimen after a lapse of 12 to 24 hours from the end of the loading dosing regimen. (1) Loading dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion every 8 hours for a total of 6 times (2) Maintenance dosing schedule: a dosing schedule in which isavuconazole or a pro-drug thereof is administered in 200mg by oral administration or intravenous drip infusion once a day in terms of isavuconazole per dose.SELECTED DRAWING: Figure 1

The article to which this design pertains is an arm cover. This article (arm cover) is used to prevent hospitalized patients from removing their intravenous drips.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses a navel therapy composition and a navel therapy preparation for preventing and treating abdominal pain caused by intravenous drip of azithromycin in children and a preparation method of the navel therapy composition and the navel therapy preparation. The technical key points are as follows: the fructus evodiae and the dysentery are combined according to a specific weight ratio, and are matched with pharmaceutic adjuvants such as a transdermal enhancer and an excipient to prepare special navel therapy dosage forms such as pills, cakes, patches and the like. According to the composition, by utilizing the characteristics that the Shenque acupoint (navel) epidermal cuticle is thin, the barrier function is weak, blood vessels are rich, and medicines are easy to disperse and absorb, adverse reactions such as gastrointestinal spasmodic pain, nausea and vomiting and the like caused by intravenous drip of azithromycin in children are effectively relieved through an administration mode of external application. Through clinical verification, the umbilical therapy preparation can remarkably reduce the incidence rate and severity score of stomachache, vomiting and diarrhea, and remarkably improve the treatment compliance of child patients.

To provide a program that outputs symptom information regarding signs of self-removal of intravenous drip. [Solution] The program acquires time-series data regarding the movement of a second hand, different from the first hand being punctured, and outputs symptom information by inputting the acquired time-series data into a learning model that outputs symptom information regarding signs of self-removal of an IV drip when time-series data is input. Preferably, the program acquires video data of the puncture site and the movement of the second hand captured by a camera, and inputs the video data into the learning model to output the symptom information.

To provide improved, stable aspirin formulations for intravenous use, as well as applications thereof.SOLUTION: A lyophilized aspirin composition is provided, the composition comprising a lyophilized mixture of crystalline aspirin in the free acid form, a bulking agent, and a surfactant. Also provided is the use of the lyophilized aspirin composition in the manufacture of a medicament for aspirin therapy by intravenous administration to a mammal in need thereof, the manufacture comprising reconstituting the lyophilized aspirin composition with water comprising a basic agent in an amount sufficient to provide an aspirin solution having a pH of at least 5.5.SELECTED DRAWING: None

The invention belongs to the field of medicines, and provides a letemovir injection and a preparation method thereof, the letemovir injection is a high-concentration letemovir injection for intravenous drip, and the letemovir injection comprises letemovir, an alkaline reagent, a pH regulator, a buffer agent, a non-aqueous solvent for injection and water for injection. According to the injection, the solubility of letemovir is greatly improved, hydroxypropyl-beta-cyclodextrin is abandoned as a solubilizer in a prescription, so that accumulated toxicity of the kidney is avoided, and the injection prescription does not contain other known solubilizers and surfactants for pharmaceutical preparations, so that the medication safety is remarkably improved; the injection can tolerate thermocompression sterilization, no visible foreign matter exists in the sterilized solution and after compatibility, the adverse reaction risk caused by capillary obstruction is avoided or reduced, and the clinical medication safety is remarkably improved; the preparation process is simple, production amplification is easy to realize, and the method has great application value.

The utility model relates to an equipment belt structure for an assembled ward. The equipment belt structure comprises a mounting unit, a main body unit, a locking unit, a hook unit and an adjusting unit, the connecting structure has the advantages that after the mounting unit is connected with the wall body, the mounting unit is connected with the main body unit in a clamping mode, traditional punching bolt fixing is replaced, damage to a prefabricated wall body structure is avoided, the integrity of the wall body and the advantages of a fabricated building are reserved, meanwhile, the mounting process is simplified, and the construction efficiency is improved; movement of the main body unit can be limited by the locking unit, loosening and displacement of the equipment belt caused by external force collision are avoided, and use safety is guaranteed. The hook unit is matched with the adjusting unit, so that the limitation that the hanging position of an infusion bottle is fixed is solved. The adjusting unit can flexibly adjust the transverse position of the hook unit according to the actual requirements of patients and the position change of the sickbed, the infusion requirements of different patients are met, and operation of medical staff is facilitated.

The application discloses a kind of oral sustained-release composition of edaravone, preparation method and application.The application provides a kind of pharmaceutical composition, it includes tablet core and coating;The tablet core includes drug-containing layer tablet core and / or boost layer tablet core;The drug-containing layer tablet core includes edaravone pharmaceutical active ingredient and carrier;The carrier is one or more in polymer carrier, osmotic pressure regulator, swelling agent, thickening agent and lubricant;The boost layer tablet core includes one or more in osmotic pressure regulator, swelling agent, colorant and lubricant.The pharmaceutical composition of the application maintains 24 hours sustained-release, oral convenient, blood drug concentration is stable, avoids the method of 2 times intravenous drip in a day, improves patient compliance.In addition, the pharmaceutical composition, prescription and preparation process are simple, easy to industrial production.

The invention discloses an application of a pharmaceutical composition in preparation of a medicine for promoting blood circulation to remove blood stasis, and relates to the technical field of traditional Chinese medicine compound preparations, the pharmaceutical composition comprises the following seven components: a Xuesaitong injection, a ginkgo dipyridamole injection, a salvia miltiorrhiza injection, an astragalus membranaceus injection, a blood pricking and bloodletting device, a Xiaoyao pill oral preparation and a pulse-activating decoction oral liquid; the application method comprises the following steps: sequentially carrying out intravenous drip injection of the Xuesaitong injection, the Ginkgo damole injection and intravenous drip of the Salvia miltiorrhiza injection; then a blood pricking and bloodletting device is used for cooperating operation; and then, carrying out intravenous drip of the astragalus membranaceus injection for administration. After injection, the Xiaoyao pills and the pulse-activating decoction are orally taken; through intravenous injection, blood pricking therapy and oral consolidated drug action paths, a new application way of the pharmaceutical composition in the blood circulation promoting and blood stasis removing drugs is provided, clear sequential use of the blood circulation promoting and blood stasis removing pharmaceutical composition is achieved, the purposes of rapid blood circulation promoting and blood stasis removing and long-acting physique conditioning of the pharmaceutical composition are achieved, and the pharmaceutical composition is safe and efficient.

The disclosed invention relates to a wearable intravenous drip device comprising: a first plate; at least one static load spring mounted on the first plate; a second plate to which a free end of a leaf spring wound around a drum of the static load spring is fixed, and which is disposed to face the first plate; and an upper arm loading part coupled to the second plate, wherein the static load springs apply elastic force causing a relative extension / contraction movement to be generated with respect to the first plate and the second plate, and the elastic force of the static load springs is constant regardless of the displacement of the leaf spring.

The article to which this design pertains is an arm cover. This article (arm cover) is used to prevent hospitalized patients from removing their intravenous drips.

The present application discloses a composition for treating painful disc injury syndrome (PDDS), disc bulging, disc herniation, and disc herniation, as well as a delivery method and recommended treatment regimen for delivering an effective dose of the composition to a patient. The composition has the characteristics of inflammation resistance, oxidation resistance, vasodilation and spasmolysis. The composition is administered by intravenous drip over a specific period of time to relieve pain.

The invention relates to the technical field of intravenous therapy data tracking, in particular to an intravenous therapy information data tracking method, system and equipment, and the method comprises the steps: determining an information effective factor of each moment in each time period of each patient; according to the difference between the intravenous drip speed at each moment in each time period and the intravenous drip speed in the neighborhood of each time period, in combination with the information effective factor, determining an intravenous therapy characteristic factor of each patient at each moment in each time period; according to the difference between the feature vectors of all data tracking moments of each patient in any time period and the feature vectors of all data tracking moments of other patients in any time period in the same type of disease group, vein treatment data of the patients are tracked. According to the method, the related data in the vein treatment process is comprehensively analyzed, the vein treatment similarity between the patients in the same type of disease group is determined, the accuracy of effective information extraction is improved, and the credibility of the vein treatment related data is enhanced.

The present invention provides a method of treating CD20 positive B cell lymphoma with Usutuzumab, involving the rate of administration of Usutuzumab. In some embodiments, the methods comprise an intravenous drip infusion at 1000 mg of ustuzumab olbabine each administration, and are administered in two or more cycles at a specific administration rate.

The utility model relates to a hospital gown, in particular to a predelivery hospital gown which is convenient for pregnant and lying-in women to put on, take off, replace and clean and is convenient for medical personnel to examine and operate. The shoulders of the hospital gown are opened and closed through the snap fasteners I and can be matched with the snap fasteners II on the front part, and the hospital gown can be directly replaced without hand intravenous drip. The detachable lower hem and the standby lower hem are arranged below the back and replaced at any time when polluted, and the puerpera is kept clean and comfortable. The rear waist part fixes a fetal heart monitor bandage through a waist loop, and bandage sub-bands branched from the two ends of the rear waist part can fix a fetal heart monitoring probe and a uterine contraction pressure probe respectively to prevent the fetal heart monitoring probe and the uterine contraction pressure probe from falling off and are convenient to store. The whole hospital gown is in an A shape, side openings are formed in the two sides of the lower portion, pulling belts are arranged on the shoulders on the two sides and used for clamping and hanging an analgesia pump, a pocket is arranged in front of the chest, no collar is arranged on the upper side, and cuffs are arranged on the shoulders. The predelivery hospital gown is high in practicability, can improve comfort and dignity of pregnant and lying-in women, reduces interference and infection risks, facilitates medical care operation and has good clinical application value.

The invention discloses a preparation method and application of a cryopreservation solution supporting high-density clinical stem cells. The cryopreservation liquid is composed of normal saline injection, human serum albumin (HSA) for injection, glucose, dimethyl sulfoxide (DMSO) for injection, hydroxyethyl starch injection, dextran injection and the like. And the high-density clinical stem cell cryopreservation liquid is prepared through accurate proportioning under the sterile condition. The application method comprises the following steps: after collecting stem cells, re-suspending and uniformly mixing the stem cells with a cryopreservation solution pre-cooled to 4 DEG C, slowly cooling to-80 DEG C by a program, and then transferring the stem cells into liquid nitrogen for long-term preservation. During resuscitation, the temperature is rapidly increased to 37 DEG C, so that the cell cryopreservation liquid is rapidly thawed, and then the cell cryopreservation liquid is recovered to room temperature and can be directly used for clinical local injection or used for intravenous drip after being diluted by normal saline.